Roche Holding's Kadcyla, or trastuzumab emtansine, has been recommended by the National Institute of Health and Care Excellence for use in women patients with advanced HER2-positive breast cancer that is inoperable even after treatment with Herceptin and a taxane, separately or together. The drug, which has been shown to extend lives of patients with terminal cancer by up to nine months, had previously been rejected by NICE as being too expensive.
NICE reverses decision, backs Roche's Kadcyla for breast cancer indication
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.